Industry Overview
The global biologics market was valued at USD 581 Bn in 2025 and is estimated to reach USD 632 Bn in 2026, reflecting a growth rate of 8.8%. Gaining growth because rising prevalence of chronic and autoimmune diseases. While high demand for precision therapeutics has created intensifying biologics adoption across oncology, infectious disease also diabetes and rare disease treatment sectors. Rising integration shifting consumer preferences towards adapting continuous bioprocessing systems with high-cell-density mammalian expression platforms, and advanced single-use biomanufacturing technologies. It is major components responsible for boosting market expansion with improve therapeutic efficacy, manufacturing scalability and product consistency. These advancement in supply chain capable for gives efficiency which significantly accelerating commercial production and regulatory compliance across biopharmaceutical industries.
Industry Insights: Scale, Segments, and Shifts
• Market Size & Growth: The global biologics market is projected to reach USD 1,455 billion by 2036, registering a CAGR of 8.7% between 2026 and 2036.
• Segment Analysis: Monoclonal Antibodies hold around 38% share with CAGR 8.8% due to rising oncology and autoimmune treatment demand, while Cell & Gene Therapy is growing fastest in the coming year because increasing personalized medicine adoption.
• Regional Highlights: North America anticipated nearly 42% share in 2025 with CAGR 7.8% through the increasing advanced manufacturing infrastructure, while Asia Pacific is expected to create to broad marketplace through expanding biosimilar production and biotechnology investments.
• Competitive Landscape: The market is moderately consolidated, with key companies such as Samsung Biologics, Amgen Inc., and Roche leading. These players shifted focus towards the expansion of continuous bioprocessing expansion and next-generation therapeutic development to strengthen global market presence.
Factors Shaping the Next Decade
• Market Gaps / Restraints: High capital required for biologics production also faces challenges related to cold chain logistics and during uncertainties in geopolitical lead disruption of supply in biopharmaceutical raw material.
• Key Trends and Innovations: Industry is witness for transformation towards adapting innovations such as continuous perfusion bioreactors and modular single-use biomanufacturing systems. Even advanced closed-cell expansion technologies are improving biologics consistency with reducing contamination risks for enhancing commercial manufacturing efficiency.
• Potential Opportunities: In future increasing development of decentralized biologics manufacturing hubs and programmable oral biologics delivery are expected to create new revenue streams in the coming year.
Recent Industry Updates:
• May 2026: Novartis broke ground on a new radioligand therapy manufacturing facility in Texas equipped with advanced biologics production infrastructure to strengthen precision cancer therapeutic manufacturing and regional supply capabilities.
• January 2026: Samsung Biologics announced to expanded their operational readiness through advanced large-scale biologics manufacturing systems for strengthened global CDMO capacity to support rising therapeutic production demand.
• September 2025: Amgen Inc. recently launched advanced biologics manufacturing expansion initiatives integrating next-generation production technologies to improve therapeutic output and operational efficiency.
• September 2025: Eli Lilly and Company announced development of a next-generation biologics manufacturing facility focused on advanced antibody and autoimmune therapeutic production technologies.
Industry Outlook Scope:
By Product Type
• Monoclonal Antibodies
• Vaccines
• Recombinant Proteins
• Cell & Gene Therapy
• Blood & Blood Components
• Tissue-Based Products
• Biosimilars
• Others
By Source
• Microbial
• Mammalian
• Plant-Based
• Transgenic Animal-Based
• Others
By End User
• Hospitals
• Specialty Clinics
• Research Institutes
• Biopharmaceutical Companies
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o UK
o Italy
o Spain
o Germany
o France
o BENELUX
o Nordics
o Rest of Europe
• Asia Pacific
o China
o India
o Japan
o South Korea
o Southeast Asia
o Australia & New Zealand
• Middle East & Africa
o Saudi Arabia
o Other GCC
o South Africa
o Rest of Middle East & Africa
• South America
o Brazil
o Chile
o Argentia
o Rest of South America
Geographical Insights: Emerging Corridors of Growth
• Regional Overview: While Europe is witnessing for rising biologics adoption due to expansion of advanced therapy medicinal product manufacturing and increasing investments in localized biosimilar production networks. In Latin America is gaining growth momentum through expansion of domestic vaccine biomanufacturing facilities and partnerships for recombinant biologics development. While Middle East & Africa is expected to holding highest share because expansion of regional biologics cold-chain infrastructure and growing investments in precision therapeutics manufacturing capabilities.
• Countries to Watch: Germany is continuous shows demand due to increasing investments in cell and Brazil is creating high adoption through expansion of domestic vaccine and biosimilar production capabilities. UAE is strengthening demand by biotechnology free-zone investments and precision medicine infrastructure.
Regulatory Environment and Policy Support
• Government Regulations & Supportive Policies: Global biologics manufacturers are aligning with several governments regulations. It includes such as the U.S. FDA Biologics License Application (BLA) framework and the European Medicines Agency Advanced Therapy Medicinal Products (ATMP) Regulation. It is helpful for ensuring standardized biologics approval with manufacturing quality compliance and therapeutic safety validation. These frameworks promoting to the commercialization of monoclonal antibodies and cell & gene therapies across global healthcare markets.
• Key Government Initiatives: Initiatives such as South Korea’s Bioeconomy 2.0 Strategy and China’s 14th Five-Year Plan for Biotechnology Development. In these way governments encouraging for investments in advanced biomanufacturing infrastructure to strengthen long-term biotechnology industry expansion.
Competitive Landscape and Strategic Outlook
The market is moderately concentrated, with leading players shifted their focus to expanding their high-capacity biologics manufacturing networks and build strong strategic CDMO partnerships. Globally well-established companies are enhancing market reach through advanced monoclonal antibody platforms also biosimilar expansion strategies and localized biomanufacturing infrastructure. While niche innovators are capturing growth by developing precision cell therapies with scalable single-use bioprocessing technologies. They trying to boosting rapid clinical-stage biologics production solutions for specialized therapeutic applications.
Industry Competition:
• Samsung Biologics
• Amgen Inc.
• Novo Nordisk A/S
• AbbVie Inc.
• Sanofi
• Johnson & Johnson Services, Inc.
• Celltrion Healthcare Co., Ltd.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann La-Roche Ltd.
• GlaxoSmithKline plc
• Merck & Co., Inc.
• Bristol Myers Squibb
• Regeneron Pharmaceuticals.
Analyst Perspective
The industry is transitioning toward enhance decentralized therapeutic manufacturing ecosystems through the adaptive biologic formulation platforms and accelerated clinical translation capabilities. During the next three to five years, market expansion is expected to drive from increasing demand for precision immunotherapies with scalable regenerative medicine production and flexible regional supply frameworks. In emerging regional companies specializing in targeted biologic delivery systems and rapid-response therapeutic manufacturing models to secure long-term competitive differentiation across global healthcare markets.
What to Expect from Outlook:
1. Save time carrying out entry-level research by identifying the size, growth trends, major segments, and leading companies in the global biologics market.
2. Use PORTER’s Five Forces analysis to assess the competitive intensity and overall attractiveness of the global biologics market sector.
3. Profiles of leading companies provide insights into key players’ regional operations, strategies, financial results, and recent initiatives.
4. Add weight to presentations and pitches by understanding the future growth prospects of the global biologics market with a forecast for the decade by both market share (%) & revenue (USD Million).
Frequently Asked Questions (FAQs)
Q1. What is the current market size of the global biologics market?
Answer: The global biologics market size was valued at USD 581.57 billion in 2025.
Q2. What is the forecast market size of the biologics market?
Answer: The biologics market is projected to reach USD 1,445 billion by 2036, supported by rising demand for precision therapeutics and expanding biologics manufacturing infrastructure.
Q3. Which category dominates the biologics market under by Type Segment?
Answer: By product type, Monoclonal Antibodies hold the largest market share of approximately 38%, owing to increasing applications across oncology and autoimmune disease treatment.
Q4. Which region leads the biologics market?
Answer: North America leads the biologics market with an estimated 42% share, driven by advanced biopharmaceutical manufacturing infrastructure and increasing biologics approvals.
Q5. Which companies are the key players in the biologics market?
Answer: Key players in the biologics market include Samsung Biologics, Amgen Inc., Novo Nordisk A/S, AbbVie Inc., Roche, Eli Lilly and Company, Sanofi, and Regeneron Pharmaceuticals.
1. Key
Findings
2. Introduction
2.1. Executive Summery
2.2. Regional Snapshot
2.3. Market Scope
2.4. Market Definition
3. Across
The Globe
3.1. Factors Affecting End Use Industries
3.2. Upcoming Opportunities
3.3. Market Dynamics
3.3.1. Ongoing Market Trends
3.3.2. Growth Driving Factors
3.3.3. Restraining Factors
3.4. Value Chain Analysis
3.4.1. List of Manufacturers
3.4.2. List of Distributors/Suppliers
3.5. PORTER’s & PESTLE Analysis
3.6. Key Developments
3.7. Key Industry Patents
3.8. Regulatory Analysis
3.9. Pricing Analysis
4. Global
Biologics Market Overview, By Product Type
4.1. Market Size (US$ Mn) Analysis, 2021 –
2036
4.2. Market Share (%) Analysis (2025 vs
2036), Y-o-Y Growth (%) Analysis (2025 - 2036) & Market Attractiveness
Analysis (2026 - 2036)
4.3. Market Absolute $ Opportunity Analysis,
2021 – 2036
4.3.1. Monoclonal Antibodies
4.3.2. Vaccines
4.3.3. Recombinant Proteins
4.3.4. Cell & Gene Therapy
4.3.5. Blood & Blood Components
4.3.6. Tissue-Based Products
4.3.7. Biosimilars
4.3.8. Others
5. Global
Biologics Market Overview, By Source
5.1. Market Size (US$ Mn) Analysis, 2021 –
2036
5.2. Market Share (%) Analysis (2025 vs
2036), Y-o-Y Growth (%) Analysis (2025 - 2036) & Market Attractiveness
Analysis (2026 - 2036)
5.3. Market Absolute $ Opportunity Analysis,
2021 – 2036
5.3.1. Microbial
5.3.2. Mammalian
5.3.3. Plant-Based
5.3.4. Transgenic Animal-Based
5.3.5. Others
6. Global
Biologics Market Overview, By End User
6.1. Market Size (US$ Mn) Analysis, 2021 –
2036
6.2. Market Share (%) Analysis (2025 vs
2036), Y-o-Y Growth (%) Analysis (2025 - 2036) & Market Attractiveness
Analysis (2026 - 2036)
6.3. Market Absolute $ Opportunity Analysis,
2021 – 2036
6.3.1. Hospitals
6.3.2. Specialty Clinics
6.3.3. Research Institutes
6.3.4. Biopharmaceutical Companies
6.3.5. Others
7. Global
Biologics Market Overview, By Region
7.1. Market Size (US$ Mn) Analysis, 2021 –
2036
7.2. Market Share (%) Analysis (2025 vs
2036), Y-o-Y Growth (%) Analysis (2025 - 2036) & Market Attractiveness
Analysis (2026 - 2036)
7.3. Market Absolute $ Opportunity Analysis,
2021 – 2036
7.3.1. North America
7.3.2. Europe
7.3.3. Asia Pacific
7.3.4. Middle East & Africa
7.3.5. South America
8. North
America Biologics Market Overview
8.1. Market Size (US$ Mn) Analysis, 2021 –
2036
8.2. Market Share (%) Analysis (2025 vs
2036), Y-o-Y Growth (%) Analysis (2025 - 2036) & Market Attractiveness
Analysis (2026 - 2036)
8.3. Market Absolute $ Opportunity Analysis,
2021 – 2036
8.3.1. By Country
8.3.1.1. U.S.
8.3.1.2. Canada
8.3.1.3. Mexico
8.3.2. By Product Type
8.3.3. By Source
8.3.4. By End User
9. Europe
Biologics Market Overview
9.1. Market Size (US$ Mn) Analysis, 2021 –
2036
9.2. Market Share (%) Analysis (2025 vs
2036), Y-o-Y Growth (%) Analysis (2025 - 2036) & Market Attractiveness
Analysis (2026 - 2036)
9.3. Market Absolute $ Opportunity Analysis,
2021 – 2036
9.3.1. By Country
9.3.1.1. UK
9.3.1.2. Italy
9.3.1.3. Spain
9.3.1.4. Germany
9.3.1.5. France
9.3.1.6. BENELUX
9.3.1.7. Nordics
9.3.1.8. Rest of Europe
9.3.2. By Product Type
9.3.3. By Source
9.3.4. By End User
10. Asia
Pacific Biologics Market Overview
10.1. Market Size (US$ Mn) Analysis, 2021 – 2036
10.2. Market Share (%) Analysis (2025 vs 2036),
Y-o-Y Growth (%) Analysis (2025 - 2036) & Market Attractiveness Analysis
(2026 - 2036)
10.3. Market Absolute $ Opportunity Analysis,
2021 – 2036
10.3.1. By Country
10.3.1.1. China
10.3.1.2. Japan
10.3.1.3. India
10.3.1.4. South Korea
10.3.1.5. Southeast Asia
10.3.1.6. Australia & New Zealand
10.3.1.7. Rest of Asia Pacific
10.3.2. By Product Type
10.3.3. By Source
10.3.4. By End User
11. Middle East
& Africa Biologics Market Overview
11.1. Market Size (US$ Mn) Analysis, 2021 – 2036
11.2. Market Share (%) Analysis (2025 vs 2036),
Y-o-Y Growth (%) Analysis (2025 - 2036) & Market Attractiveness Analysis
(2026 - 2036)
11.3. Market Absolute $ Opportunity Analysis,
2021 – 2036
11.3.1. By Country
11.3.1.1. Saudi Arabia
11.3.1.2. Other GCC
11.3.1.3. South Africa
11.3.1.4. Rest of Middle East & Africa
11.3.2. By Product Type
11.3.3. By Source
11.3.4. By End User
12. South
America Biologics Market Overview
12.1. Market Size (US$ Mn) Analysis, 2021 – 2036
12.2. Market Share (%) Analysis (2025 vs 2036),
Y-o-Y Growth (%) Analysis (2025 - 2036) & Market Attractiveness Analysis
(2026 - 2036)
12.3. Market Absolute $ Opportunity Analysis,
2021 – 2036
12.3.1. By Country
12.3.1.1. Brazil
12.3.1.2. Chile
12.3.1.3. Argentina
12.3.1.4. Rest of South America
12.3.2. By Product Type
12.3.3. By Source
12.3.4. By End User
13. Country
Wise Market Analysis
13.1. Growth Comparison by Key Countries
13.1.1. Market Size Analysis, by Segmentation
(U.S. Canada, Mexico, UK, Italy, Spain, Germany, France,
BENELUX, Nordics, Rest of Europe, China, India, Japan, South Korea, Southeast
Asia, Australia & New Zealand, Saudi Arabia, Other GCC, South Africa, Rest
of Middle East & Africa, Brazil, Chile, Argentia, Rest of South America)
14. Competitive
Landscape
14.1. Market Share (%) Analysis, By Top Players
14.2. Market Structure Analysis, By Tier I &
II Companies
15. Company
Profiles
15.1. Samsung Biologics
15.1.1. Company Overview
15.1.2. Business Segments
15.1.3. Financial Insights
15.1.4. Key Business Aspects (Noise Analysis)
15.2. Amgen Inc.
15.3. Novo Nordisk A/S
15.4. AbbVie Inc.
15.5. Sanofi
15.6. Johnson & Johnson Services, Inc.
15.7. Celltrion Healthcare Co., Ltd.
15.8. Bristol-Myers Squibb Company
15.9. Eli Lilly and Company
15.10. F. Hoffmann La-Roche Ltd.
15.11. GlaxoSmithKline plc
15.12. Merck & Co., Inc.
15.13. Bristol Myers Squibb
15.14. Regeneron Pharmaceuticals
16. Analysis
& Recommendations
17. Research
Methodology
18. Disclaimer
